-transparent.png){kind=logo}
Long term use of ovine corticotropin-releasing hormone (oCRH) requires a convenient route of administration. The effects of 0.3, 3, and 30 micrograms/kg BW synthetic oCRH given as a sc injection and of 10 and 30 micrograms/kg given as an intranasal spray were studied in 10 normal men in the late afternoon. Basal plasma immunoreactive ACTH (IR-ACTH) and IR-cortisol levels were 14 +/- 1.9 pg/ml and 4.3 +/- 0.4 microgram/dl (mean +/- SEM). Peak IR-ACTH levels (mean +/- SEM) were 43 +/- 5.5, 53 +/- 8.1, and 64 +/- 8.9 pg/ml after the 0.3, 3, and 30 micrograms/kg doses of oCRH given sc, respectively, and 23 +/- 4.3 and 36 +/- 4.8 pg/ml after the 10 and 30 micrograms/kg doses of oCRH given intranasally, respectively. The lowest sc dose and both intranasal doses caused only single IR-ACTH peaks. After 3 and 30 micrograms/kg sc oCRH, IR-ACTH rose by 15 min, reached an initial peak at 45-60 min, fell rapidly until 90-120 min, and rose to a second peak at 3-5 h. This biphasic response is similar to that previously found after iv administration. IR-ACTH levels remained elevated for 4, 10, and at least 16 h after 0.3, 3, and 30 micrograms/kg sc oCRH, respectively, and for 1.5 and 3 h after 10 and 30 micrograms/kg intranasal oCRH respectively. The effect on IR-cortisol was similar, but more prolonged. Compared to the iv route, sc oCRH produced similar mean peak IR-ACTH and IR-cortisol levels and had a slightly longer duration of action. Intranasal oCRH was only about 1% as effective. Peak plasma IR-oCRH levels in 2 subjects receiving 3 micrograms/kg sc oCRH were 13 and 17 ng/ml at 90 min. These peaks were lower than those after iv administration of the same dose, but the levels remained elevated longer, probably accounting for the longer duration of action of sc oCRH. Peak plasma IR-oCRH levels in 4 subjects given 10 microgram/kg intranasal oCRH were only 64-122 pg/ml, presumably reflecting poor absorption through the nasal mucosa. These results demonstrate that sc injection of oCRH is at least as effective as the iv route with respect to plasma IR-ACTH and IR-cortisol responses. The convenience of this route of administration and the prolonged duration of action of oCRH suggest the feasibility of long term oCRH use.
C R DeBold, and
W R Sheldon, and
G S DeCherney, and
R V Jackson, and
W E Nicholson, and
D P Island, and
D N Orth
December 1986,
The Journal of clinical endocrinology and metabolism,
C R DeBold, and
W R Sheldon, and
G S DeCherney, and
R V Jackson, and
W E Nicholson, and
D P Island, and
D N Orth
April 1992,
The American journal of the medical sciences,
C R DeBold, and
W R Sheldon, and
G S DeCherney, and
R V Jackson, and
W E Nicholson, and
D P Island, and
D N Orth
March 1991,
Klinische Wochenschrift,
C R DeBold, and
W R Sheldon, and
G S DeCherney, and
R V Jackson, and
W E Nicholson, and
D P Island, and
D N Orth
March 1994,
The Journal of clinical endocrinology and metabolism,
C R DeBold, and
W R Sheldon, and
G S DeCherney, and
R V Jackson, and
W E Nicholson, and
D P Island, and
D N Orth
December 1986,
Experimental and clinical endocrinology,
C R DeBold, and
W R Sheldon, and
G S DeCherney, and
R V Jackson, and
W E Nicholson, and
D P Island, and
D N Orth
January 2013,
Journal of veterinary internal medicine,
C R DeBold, and
W R Sheldon, and
G S DeCherney, and
R V Jackson, and
W E Nicholson, and
D P Island, and
D N Orth
November 1974,
The Journal of endocrinology,
C R DeBold, and
W R Sheldon, and
G S DeCherney, and
R V Jackson, and
W E Nicholson, and
D P Island, and
D N Orth
November 1986,
Lancet (London, England),
C R DeBold, and
W R Sheldon, and
G S DeCherney, and
R V Jackson, and
W E Nicholson, and
D P Island, and
D N Orth
June 1985,
The Journal of clinical investigation,
C R DeBold, and
W R Sheldon, and
G S DeCherney, and
R V Jackson, and
W E Nicholson, and
D P Island, and
D N Orth
May 2017,
American journal of physiology. Gastrointestinal and liver physiology,
